ChromaDex (United States)

ChromaDex (United States)

Niagen Bioscience, formerly ChromaDex, is a bioscience сompany based in Los Angeles, California founded in 1999. The company operates in multiple sectors including reference standards, dietary supplements, and ingredient technology. Niagen Bioscience is publicly traded on the NASDAQ. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for ChromaDex (United States), United States, covering academic research published from 2003 to 2024. Read More.


Open Access Percentage

59%


Total
Publications

68


Total Open
Publications

40


Total
Citations

2.8K


Open Access
Percentage

59%


Total
Publications

68


Total Open
Publications

40


Total
Citations

2.8K

Wikipedia

Website

download

Breakdown

32% 23% 3% 42%

Publisher Open

32%

Both

23%

Other Platform Open

3%

Closed

42%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

00.511.522.533.544.555.566.57Total Publications
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

28%OA Journal

OA Journal 28%

10

Hybrid 39%

14

No Guarantees 33%

12

Other Platform Open

Domain 88%

15

Institution 29%

5

Other Internet 12%

2

Preprint 0%

0

Public 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
15
DANS - Data Archiving and Networked Services
Institution
3
VU Research Portal
Institution
2
Elsevier - Scopus
Institution
2
ZB MED - Informationszentrum Lebenswissenschaften
Institution
1
Unknown Repository
Other Internet
1
University of Oslo - Duo Research Archive
Institution
1
University of Florence - Florence Research
Institution
1
Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona
Institution
1
Queen's University Belfast - Research Portal
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share